Biomea Fusion Crashes 65% After FDA Puts Diabetes Treatment Studies On Hold
Biomea stock crashed Friday after the FDA placed two of the company's diabetes treatment studies on hold, citing concerns of liver toxicity.
Why Is Biomea Fusion (BMEA) Stock Down 63% Today?
Biomea Fusion (NASDAQ: BMEA ) stock is falling hard on Friday after announcing a clinical hold has been put on its Phase I/II clinical trials of BMF-219. This clinical hold comes from the Food and Drug Administration (FDA) and has to do with safety concerns.
Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze
One of the fastest ways to make money on the stock market is to gamble on short-term contrarian positions against the shorting interest of a stock. Since every company's proportion of shorted stock is publicly available, it's pretty easy to see which companies are expected to lose value.
Short Squeeze Specialists: 3 Stocks With the Expertise to Defy Bearish Expectations
For those seeking blistering returns in a relatively short amount of time, short-squeeze stocks may be the go-to place. Here, contrarians leverage the power of psychology to the extreme, leading to possibly intense fervor.
